Abstract
Advanced pancreatic ductal adenocarcinoma (PDAC) responds poorly to conventional delivery of chemotherapeutic agents, with a 5-year survival rate of only 10%.1 PDAC tends to elicit a dense desmoplastic reaction which restricts blood flow and absorption of therapeutics. This study describes the development of a trans-venous approach for regional treatment of pancreatic tumors, called pancreatic retrograde venous infusion (PRVI), using a catheter capable of modulating pressure and flow within the organ to promote drug uptake.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
